Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID N OUBRE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1104883305
CMS profile
321762
Location
HAMMOND, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$10,256.24

178 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Sobi, Inc $6,688.00 8
Novartis Pharmaceuticals Corporation $234.88 14
E.R. Squibb & Sons, L.L.C. $226.53 7
ASD Specialty Healthcare, LLC $211.89 1
EISAI INC. $197.12 11
AstraZeneca Pharmaceuticals LP $182.30 10
Rigel Pharmaceuticals, Inc. $164.86 5
Celgene Corporation $149.63 9
Takeda Pharmaceuticals U.S.A., Inc. $143.75 7
Amgen Inc. $142.36 8
PFIZER INC. $139.60 8
Merck Sharp & Dohme LLC $135.43 7
Janssen Biotech, Inc. $122.95 6
Incyte Corporation $119.21 7
Pharmacyclics LLC, an AbbVie Company $105.47 6
GENZYME CORPORATION $99.59 6
GlaxoSmithKline, LLC. $92.96 5
Regeneron Healthcare Solutions, Inc. $85.00 1
Kite Pharma, Inc. $84.15 1
Daiichi Sankyo Inc. $83.71 4
Bayer HealthCare Pharmaceuticals Inc. $58.16 3
Genentech USA, Inc. $55.81 3
Blueprint Medicines Corporation $50.40 3
EMD Serono, Inc. $50.00 3
Myovant Sciences Inc. $47.83 3
Boehringer Ingelheim Pharmaceuticals, Inc. $45.96 2
AVEO Pharmaceuticals, Inc. $40.30 2
Taiho Oncology, Inc. $38.03 2
Gilead Sciences, Inc. $36.61 2
MorphoSys, US Inc. $35.55 2
Seagen Inc. $34.20 2
Alexion Pharmaceuticals, Inc. $32.57 2
Lilly USA, LLC $32.40 2
Astellas Pharma US Inc $23.16 1
Janssen Pharmaceuticals, Inc $21.76 1
Exelixis Inc. $20.63 1
Pharmacosmos Therapeutics Inc. $19.61 1
Deciphera Pharmaceuticals Inc. $19.59 1
Karyopharm Therapeutics Inc. $19.43 1
Agios Pharmaceuticals, Inc. $19.06 1
Kyowa Kirin, Inc. $18.79 1
PharmaEssentia USA Corporation $17.63 1
BeiGene USA, Inc. $17.34 1
CTI BioPharma Corp. $17.23 1
Myriad Genetic Laboratories, Inc. $16.45 1
ABBVIE INC. $16.39 1
G1 Therapeutics, Inc. $15.01 1
PUMA BIOTECHNOLOGY, INC. $14.01 1
AMAG Pharmaceuticals, Inc. $12.94 1

Page 4 of 4; records 151–178 of 178 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID N OUBRE

NPI 1104883305 · CMS profile ID 321762

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

HAMMOND, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–178 of 178 matching records. This page contains 28 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1104883305?year=2022&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID N OUBRE, NPI 1104883305, CMS profile ID 321762. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–178 of 178 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104883305?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). DAVID N OUBRE, NPI 1104883305, CMS profile ID 321762. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–178 of 178 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104883305?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
DAVID N OUBRE, NPI 1104883305, CMS profile ID 321762, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–178 of 178 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1104883305?year=2022&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

178 matching records · $10,256.24 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 178 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–178 of 178.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech USA, Inc. $17.5502/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950797209 CMS
Genentech USA, Inc. $15.8302/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950800249 CMS
Sobi, Inc $16.8302/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940378445 CMS
Janssen Biotech, Inc. $22.5902/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885955737 CMS
Novartis Pharmaceuticals Corporation $4.1902/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894048761 CMS
Alexion Pharmaceuticals, Inc. $18.2902/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914626393 CMS
Pharmacyclics LLC, an AbbVie Company $18.0502/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890345237 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.5602/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955762641 CMS
Myovant Sciences Inc. $15.6102/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941230245 CMS
Merck Sharp & Dohme LLC $16.5302/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944085313 CMS
Lilly USA, LLC $19.8702/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917994995 CMS
AstraZeneca Pharmaceuticals LP $20.3101/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914761481 CMS
Blueprint Medicines Corporation $16.0101/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958934147 CMS
Novartis Pharmaceuticals Corporation $17.0201/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894048769 CMS
Novartis Pharmaceuticals Corporation $16.6801/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894048765 CMS
Sobi, Inc $1,540.0001/25/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940378441 CMS
Merck Sharp & Dohme LLC $17.9701/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944327149 CMS
AMAG Pharmaceuticals, Inc. $12.9401/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 953401639 CMS
Pharmacyclics LLC, an AbbVie Company $12.5301/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890345235 CMS
EISAI INC. $18.1101/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908030813 CMS
Incyte Corporation $17.0701/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943023227 CMS
Novartis Pharmaceuticals Corporation $12.3901/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894048753 CMS
Celgene Corporation $12.2701/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932816481 CMS
Rigel Pharmaceuticals, Inc. $17.9101/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 962265545 CMS
Karyopharm Therapeutics Inc. $19.4301/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946515335 CMS
Novartis Pharmaceuticals Corporation $17.6701/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894048757 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.9401/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887352199 CMS
PFIZER INC. $16.3901/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949057793 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $16,166.05 172
PY2020 $31,417.70 167
PY2021 $4,554.00 173
PY2022 $10,256.24 178
PY2023 $7,949.49 172
PY2024 $3,206.94 137
PY2025 $7,476.90 143

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,000.00 1
PY2025 Principal investigator $250,356.91 41
PY2024 Recipient $1,118.04 1
PY2024 Principal investigator $195,442.52 39
PY2023 Recipient $19,675.45 3
PY2023 Principal investigator $132,488.19 39
PY2022 Recipient $22.00 1
PY2022 Principal investigator $79,561.90 36
PY2021 Recipient $2,540.00 4
PY2021 Principal investigator $128,754.64 38
PY2020 Recipient $8,022.35 1
PY2020 Principal investigator $297,002.22 29
PY2019 Recipient $53,131.54 1
PY2019 Principal investigator $200,942.12 48

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

42 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient E.R. Squibb & Sons, L.L.C. $1,000.00 12/03/2025 Covered Recipient Physician A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome in Erythropoiesis-Stimulating Agent naive Participants who are Non-Transfusion Dependent No dispute reported 06/30/2026 1236002081
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 11/20/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175298827
Principal investigator 1 AstraZeneca Pharmaceuticals LP $28,555.00 09/12/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
Artemide Lung02 a phase III global study of rilvegostomig or pembrolizumab for patients with metastatic squamous non small cell lung cancer No dispute reported 06/30/2026 1185543422
Principal investigator 1 ABBVIE INC. $3,650.00 08/15/2025 Non-covered Recipient Entity
QCCA NETWORK LLC
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202504963
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $669.65 08/08/2025 Non-covered Recipient Entity
Pontchartrain Cancer Center
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome in Erythropoiesis-Stimulating Agent naive Participants who are Non-Transfusion Dependent No dispute reported 06/30/2026 1235994587
Principal investigator 1 BeOne Medicines USA, Inc. $5,165.00 07/29/2025 Non-covered Recipient Entity
Pontchartrain Cancer Center
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190329209
Principal investigator 1 BeOne Medicines USA, Inc. $2,350.00 07/22/2025 Non-covered Recipient Entity
Pontchartrain Cancer Center
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190333090
Principal investigator 1 BeOne Medicines USA, Inc. $3,668.00 06/17/2025 Non-covered Recipient Entity
Pontchartrain Cancer Center
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190326064
Principal investigator 1 ABBVIE INC. $1,200.00 06/12/2025 Non-covered Recipient Entity
QCCA NETWORK LLC
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202491105
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,550.00 05/30/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) No dispute reported 06/30/2026 1185543429
Principal investigator 1 BeOne Medicines USA, Inc. $11,074.00 05/30/2025 Non-covered Recipient Entity
Pontchartrain Cancer Center
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190326062
Principal investigator 1 BeOne Medicines USA, Inc. $1,902.00 05/30/2025 Non-covered Recipient Entity
Pontchartrain Cancer Center
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190331387
Principal investigator 1 Janssen Research & Development, LLC $750.88 05/28/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175299140
Principal investigator 1 Janssen Research & Development, LLC $426.40 05/28/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175299362
Principal investigator 1 Mirati Therapeutics, Inc. $7,440.00 05/28/2025 Non-covered Recipient Entity
Exigent Research Llc
A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation No dispute reported 06/30/2026 1236531150
Principal investigator 1 Janssen Research & Development, LLC $6,500.00 05/09/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175299424
Principal investigator 1 GENZYME CORPORATION $31,810.00 05/05/2025 Non-covered Recipient Entity
Exigent Research Llc
A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226109187
Principal investigator 1 Janssen Research & Development, LLC $5,000.00 04/30/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175299476
Principal investigator 1 Janssen Research & Development, LLC $750.88 04/28/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175298376
Principal investigator 1 Janssen Research & Development, LLC $1,391.91 04/28/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175298475
Principal investigator 1 Janssen Research & Development, LLC $1,391.91 04/28/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175298553
Principal investigator 1 Janssen Research & Development, LLC $750.88 04/28/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175299063
Principal investigator 1 Janssen Research & Development, LLC $750.88 04/28/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175299126
Principal investigator 1 Janssen Research & Development, LLC $426.40 04/28/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175299181
Principal investigator 1 Janssen Research & Development, LLC $750.88 04/28/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175299579
Principal investigator 1 Janssen Research & Development, LLC $750.88 04/28/2025 Non-covered Recipient Entity
Exigent Rsrch Llc
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175299587
Principal investigator 1 Mirati Therapeutics, Inc. $2,641.21 04/28/2025 Non-covered Recipient Entity
Oncare Alliance, Llc
A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Ther No dispute reported 06/30/2026 1236530821
Principal investigator 1 BeOne Medicines USA, Inc. $3,668.00 04/22/2025 Non-covered Recipient Entity
Pontchartrain Cancer Center
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190326066
Principal investigator 1 BeOne Medicines USA, Inc. $1,941.00 04/22/2025 Non-covered Recipient Entity
Pontchartrain Cancer Center
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190331385
Principal investigator 1 BeOne Medicines USA, Inc. $7,815.00 03/25/2025 Non-covered Recipient Entity
Pontchartrain Cancer Center
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190326060
Principal investigator 1 BeOne Medicines USA, Inc. $960.00 03/25/2025 Non-covered Recipient Entity
Pontchartrain Cancer Center
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190338620
Principal investigator 1 BeiGene USA, Inc. $19,065.00 03/11/2025 Non-covered Recipient Entity
Pontchartrain Cancer Center
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190322490
Principal investigator 1 AstraZeneca UK Limited $3,733.63 02/26/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
an observational,prospective,multicenter study of non small cell lung cancer patients in the US receiving standard of care and initiating an approved therapy with risk of pneumonitis ILD No dispute reported 06/30/2026 1185543426
Principal investigator 1 BeiGene USA, Inc. $2,133.00 02/20/2025 Non-covered Recipient Entity
Pontchartrain Cancer Center
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190322488
Principal investigator 1 Celgene Corporation $5,450.00 02/19/2025 Non-covered Recipient Entity
Oncare Alliance, Llc
Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. The purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. No dispute reported 06/30/2026 1222306565
Principal investigator 1 Genentech, Inc. $1,250.00 02/05/2025 Non-covered Recipient Entity
PONTCHARTRAIN CANCER CENTER
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211638761
Principal investigator 1 Genentech, Inc. $1,400.00 02/05/2025 Non-covered Recipient Entity
PONTCHARTRAIN CANCER CENTER
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211638766
Principal investigator 1 Genentech, Inc. $1,728.00 02/05/2025 Non-covered Recipient Entity
PONTCHARTRAIN CANCER CENTER
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211638770
Principal investigator 1 Genentech, Inc. $1,750.00 02/05/2025 Non-covered Recipient Entity
PONTCHARTRAIN CANCER CENTER
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211638774
Principal investigator 1 BeiGene USA, Inc. $1,200.00 01/28/2025 Non-covered Recipient Entity
Pontchartrain Cancer Center
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190322486
Principal investigator 1 Eli Lilly and Company $279.52 01/09/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187888336
Principal investigator 1 Eli Lilly and Company $75,667.00 01/07/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187888326